AU7770291A - Liposomes with positive excess charge - Google Patents

Liposomes with positive excess charge

Info

Publication number
AU7770291A
AU7770291A AU77702/91A AU7770291A AU7770291A AU 7770291 A AU7770291 A AU 7770291A AU 77702/91 A AU77702/91 A AU 77702/91A AU 7770291 A AU7770291 A AU 7770291A AU 7770291 A AU7770291 A AU 7770291A
Authority
AU
Australia
Prior art keywords
liposomes
formula
pnn
gly
excess charge
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU77702/91A
Other versions
AU643282B2 (en
Inventor
Hansjorg Eibl
Petra Kaufmann-Kolle
Clemens Unger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften eV filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Publication of AU7770291A publication Critical patent/AU7770291A/en
Application granted granted Critical
Publication of AU643282B2 publication Critical patent/AU643282B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dispersion Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

New liposome structures are characterized by having at least 1 mol % of a compound with a positive excess charge having general formula (I), in which R1? represents alkoyl or alkyl mit 14 to 18 C atoms, oleoyl or oleyl; R2? has the same meaning as R1? (although R1? need not be identical to R2?) and furthermore PNN, having formula (a), or Gly, having formula (b), in which A may represent -NH3??+, -NH2?CH3??+, -NH(CH3?)?+2?, N(CH3?)?+3?; R3? represents -O-R1?, -O-PNN, -O-Gly, NH3??+, NH2?CH3??+, NH(CH3?)2??+ or N(CH3?)3??+; R has one of the meanings given for R1?, R2? or R3?; and n is an integer between 0 and 3, preferably 0, provided that the molecule contains one of the above-mentioned groups with a positive charge. Because of their organ-specific behaviour, these liposomes are very useful as excipients in medicinal compositions for treating liver diseases which contain in the disclosed liposomes one or several liver-active substances.
AU77702/91A 1990-04-27 1991-04-25 Liposomes with positive excess charge Ceased AU643282B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4013632A DE4013632A1 (en) 1990-04-27 1990-04-27 LIPOSOMES WITH POSITIVE EXCESS CHARGE
DE4013632 1990-04-27

Publications (2)

Publication Number Publication Date
AU7770291A true AU7770291A (en) 1991-11-27
AU643282B2 AU643282B2 (en) 1993-11-11

Family

ID=6405307

Family Applications (1)

Application Number Title Priority Date Filing Date
AU77702/91A Ceased AU643282B2 (en) 1990-04-27 1991-04-25 Liposomes with positive excess charge

Country Status (11)

Country Link
EP (1) EP0526531B1 (en)
JP (1) JPH05506661A (en)
AT (1) ATE107503T1 (en)
AU (1) AU643282B2 (en)
CA (1) CA2081119A1 (en)
DE (2) DE4013632A1 (en)
DK (1) DK0526531T3 (en)
ES (1) ES2056648T3 (en)
IE (1) IE62548B1 (en)
PT (1) PT97500B (en)
WO (1) WO1991016880A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU672600B2 (en) * 1992-03-17 1996-10-10 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Liposomes with excess negative charge

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH087409B2 (en) * 1988-10-03 1996-01-29 富士写真フイルム株式会社 Processing method of silver halide color photographic light-sensitive material
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5552155A (en) * 1992-12-04 1996-09-03 The Liposome Company, Inc. Fusogenic lipsomes and methods for making and using same
EP0702516A4 (en) 1993-06-01 1998-04-22 Life Technologies Inc Genetic immunization with cationic lipids
EP0638639B1 (en) * 1993-08-10 2000-04-12 Akzo Nobel N.V. Biodegradable fabric softening composition
EP0758883B1 (en) * 1994-04-12 2003-03-19 The Liposome Company, Inc. Fusogenic liposomes and methods of making and using same
US5429755A (en) * 1994-06-16 1995-07-04 Lever Brothers Company Fabric conditioning molecules derived from glycerol and betaine
DE69600850T2 (en) * 1995-02-24 1999-04-15 Kao Corp Quaternized ammonium salts, processes for their preparation and fabric softening compositions containing them
WO1997019675A2 (en) 1995-11-30 1997-06-05 Vical Incorporated Complex cationic lipids
DE19835611A1 (en) 1998-08-06 2000-02-10 Max Planck Gesellschaft Novel phospholipids with synthetic, unsaturated alkyl and acyl chains
US20030229037A1 (en) * 2000-02-07 2003-12-11 Ulrich Massing Novel cationic amphiphiles
ITMI20032185A1 (en) * 2003-11-12 2005-05-13 Chemi Spa PROCESS FOR THE SYNTHESIS OF CATIONIC LIPIDS.
DE102004057303A1 (en) * 2004-11-26 2006-06-01 Merck Patent Gmbh Stable crystal modifications of DOTAP chloride
CA3144493A1 (en) * 2006-10-03 2008-04-10 Arbutus Biopharma Corporation Lipid containing formulations
EP2575764B1 (en) * 2010-06-03 2017-04-19 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
ES2911505T3 (en) * 2010-10-06 2022-05-19 Inst Catalana Recerca Estudis Avancats Method for the diagnosis, prognosis and treatment of breast cancer metastasis
SG10201706859QA (en) 2011-05-20 2017-09-28 Merck Patent Gmbh Stable crystal modifications of dotap chloride
JP2013043885A (en) * 2011-08-26 2013-03-04 Kansai Bunri Sogo Gakuen Dehydroamino acid-containing glycerol derivative
CA2856742A1 (en) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
CN117230193A (en) 2016-05-25 2023-12-15 生物运动有限公司 C-MAF state based therapeutic treatment of breast cancer
EP3713581A1 (en) 2017-11-22 2020-09-30 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf
KR102054401B1 (en) * 2018-03-26 2019-12-10 주식회사 엔지켐생명과학 1,2-diacylglycerol compound, method for preparing the same and immunomodulating agent including the same as active ingredient
JP2024068648A (en) * 2022-11-08 2024-05-20 美洛生物科技股▲ふん▼有限公司 Cationic lipids and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2752553C2 (en) * 1977-11-24 1985-07-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Novel phospholipid-like compounds, their use in the manufacture of plant hybrids and processes for their manufacture
AU5632880A (en) * 1979-04-30 1980-11-06 Brown, G. Convertible sleeping and seating apparatus
DE3374837D1 (en) * 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
CA1288774C (en) * 1985-01-07 1991-09-10 Deborah A. Eppstein 1,2-dialkoxy-w-trialkylammonium cationic surfactants
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
JPS632921A (en) * 1986-06-20 1988-01-07 Yamanouchi Pharmaceut Co Ltd Liposome preparation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU672600B2 (en) * 1992-03-17 1996-10-10 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Liposomes with excess negative charge

Also Published As

Publication number Publication date
EP0526531B1 (en) 1994-06-22
AU643282B2 (en) 1993-11-11
IE911427A1 (en) 1991-11-06
IE62548B1 (en) 1995-02-08
DE59102030D1 (en) 1994-07-28
PT97500B (en) 1998-08-31
JPH05506661A (en) 1993-09-30
DK0526531T3 (en) 1994-08-22
DE4013632A1 (en) 1991-10-31
CA2081119A1 (en) 1991-10-28
ES2056648T3 (en) 1994-10-01
WO1991016880A1 (en) 1991-11-14
ATE107503T1 (en) 1994-07-15
PT97500A (en) 1992-01-31
EP0526531A1 (en) 1993-02-10

Similar Documents

Publication Publication Date Title
AU643282B2 (en) Liposomes with positive excess charge
CA2078790A1 (en) 3-benzylidene-1-carbamoyl-2-pyrrolidone analogues
CA2200316A1 (en) Imidazole derivative
NO950849D0 (en) Derivatives of valproin and 2-valproic acid amides and use as anticonvulsants
ES2139079T3 (en) IMMUNOSUPPRESSIVE AND ANTIALLERGIC COMPOUNDS, SUCH AS N- (3-OXOHEXANOIL) -HOMOSERINE-LACTONE.
TR200102038T2 (en) Amide components
ES431454A1 (en) Novel 1-phthalazone derivative, a process for its preparation and a pharmaceutical composition containing it
ES2169150T3 (en) DIHYDROBENZOFURANE BASED COMPOUNDS AND RELATED COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS.
DE69420012D1 (en) Doxorubicine encapsulating liposomes
ES8200011A1 (en) Pharmaceutical composition containing a diphenylhydantoin derivative, derivatives used and their preparation.
ES482782A1 (en) Imidazole derivatives
ES429234A1 (en) N-(1-({107 -phenyl-alkyl)-piperidyl-4)-N-({60 -pyridyl)-carboxylic acid amides and salts thereof
EA199801028A1 (en) APPLICATION OF DERIVATIVES OF P-AMINOPHENOL FOR PREPARATION OF PHARMACEUTICAL COMPOSITIONS USED IN THE TREATMENT OF NEURODEGENERATIVE DISEASES
BG104717A (en) Water soluble azoles as broad-spectrum antifungals
ATE171943T1 (en) PIPERIDINE COMPOUNDS, THEIR PRESENTATION AND THEIR USE
DE69529624D1 (en) NEW ENDIYN-CHINONIMINE AND METHOD FOR THE PRODUCTION AND USE THEREOF
IL125926A0 (en) Compounds related to the amidinium family pharmaceutical compositions containing them and uses thereof
IE44765L (en) N-substituted benzamides.
SE8600046L (en) USE OF AN ESTER SOCIETY THAT TEMPORES BACTERICID AND PRODUCT CONTAINING THE ESTER SOCIETY
DE69330601D1 (en) SEROTON INERGIC ERGOLIN DERIVATIVES
SE8303913L (en) Heterocyclic Associations
DE3786865D1 (en) ANTI-CONVULSIVE COMPOSITIONS CONTAINING AMINO ACID DERIVATIVES AND USE OF THESE AMINO ACID DERIVATIVES.
HUP0003475A2 (en) Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase
HUP9803028A2 (en) Cyclic nitrones and pharmaceutical compositions containing them
TR199902433T2 (en) New pyridine derivatives and pharmaceutical compositions containing them.